Skip to main content Back to Top
Advertisement

7/22/2022

Iodixanol Injection

Products Affected - Description

    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-02
    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-17
    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 150 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-03
    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 150 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-19
    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 200 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-21
    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-01
    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-16
    • Visipaque solution for injection, GE Healthcare, 270 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-2222-23
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-02
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 150 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-19
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 150 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-03
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 200 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-04
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 200 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-21
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-06
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 50 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-16
    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 500 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-23

Reason for the Shortage

    • The GE Healthcare production facility for iodinated contrast media located in Shanghai, China was shut down temporarily due to a COVID-19 lockdown. The facility is open again and operating at full capacity. Some Visipaque presentations are available now.
    • Fresenius Kabi launched iodixanol in mid-July 2022. The company is marketing and distributing iodixanol for Jiangsu Hergrui Pharmaceuticals in the US.

Available Products

    • Visipaque solution for injection, GE Healthcare, 320 mg/mL, 100 mL +PLUSPAK bottle, 10 count, NDC 00407-2223-17
    • Iodixanol solution for injection, Fresenius Kabi, 270 mg/mL, 100 mL bottle, 10 count, NDC 65219-0381-10
    • Iodixanol solution for injection, Fresenius Kabi, 270 mg/mL, 150 mL bottle, 10 count, NDC 65219-0381-50
    • Iodixanol solution for injection, Fresenius Kabi, 320 mg/mL, 100 mL bottle, 10 count, NDC 65219-0383-10
    • Iodixanol solution for injection, Fresenius Kabi, 320 mg/mL, 150 mL bottle, 10 count, NDC 65219-0383-50
    • Iodixanol solution for injection, Fresenius Kabi, 320 mg/mL, 200 mL bottle, 10 count, NDC 65219-0383-70
    • Iodixanol solution for injection, Fresenius Kabi, 320 mg/mL, 50 mL bottle, 10 count, NDC 65219-0383-05

Estimated Resupply Dates

    • GE Healthcare has Visipaque 270 mg/mL 100 mL +PLUSPAK in 10 count (NDC 00407-2222-17) on back order and the company estimates a release date in late-August 2022. Other presentations are on back order and the company estimates a release date in late-2022.

Alternative Agents & Management

    • More information can be found at Considerations for Imaging Contrast Shortage Management and Conservation
    • Non-ionic, low osmolality contrast media in current use include iopamidol, iohexol, iopromide, and ioversol.
    • Iodixanol (iso-osmolality agent) is also included in the low osmolality contrast media category.[1]
    • The American College of Radiology (ACR) has issued a statement addressing the shortage of iodinated contrast media. https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Contrast-Media-Shortage

References

    1. ACR Manual on Contrast Media. American College of Radiology. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. 2021.

Updated

Updated July 22, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 12, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.